Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

The treatment landscape for advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has evolved rapidly, with a surge of biomarkers, therapies, and clinical trial data reshaping standards of care. This dynamic, expert-led live webinar is designed to help you navigate these changes with confidence, bringing clarity to biomarker testing guidelines, biomarker-driven frontline therapy selection, and toxicity management. Through gamified case challenges and live polling, you'll actively apply the latest evidence to practice and sharpen your decision-making skills to advance patient care.